

Hebert Alberto Vargas

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/7740576/publications.pdf>

Version: 2024-02-01

126
papers

6,730
citations

66343
42
h-index

66911
78
g-index

130
all docs

130
docs citations

130
times ranked

9204
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Utility of MRI Features in Intradiverticular Bladder Tumor. Academic Radiology, 2022, 29, 219-228.	2.5	6
2	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79.	1.9	2
3	The role of MRI in prostate cancer: current and future directions. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 503-521.	2.0	7
4	Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. Radiology, 2022, 302, 595-602.	7.3	12
5	Quantitative versus Subjective Analysis of Dynamic Contrast-enhanced MRI for O-RADS?. Radiology, 2022, 303, 576-577.	7.3	6
6	Abbreviated MR Protocols in Prostate MRI. Life, 2022, 12, 552.	2.4	0
7	MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clinical Genitourinary Cancer, 2022, , .	1.9	6
8	Comparison of PI-RADS Versions 2.0 and 2.1 for MRI-based Calculation of the Prostate Volume. Academic Radiology, 2021, 28, 1548-1556.	2.5	8
9	Radiomics and radiogenomics in ovarian cancer: a literature review. Abdominal Radiology, 2021, 46, 2308-2322.	2.1	41
10	Commentary on "Prostate-Specific Membrane Antigen PET-CT in Patients With High-Risk Prostate Cancer Before Curative-Intent Surgery or Radiotherapy (proPSMA): a Prospective, Randomised, Multicentre Study" American Journal of Roentgenology, 2021, 216, 310-310.	2.2	0
11	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸ F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056.	5.0	19
12	Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study. Cancer Imaging, 2021, 21, 24.	2.8	13
13	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research, 2021, 27, 3845-3853.	7.0	25
14	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. Journal of Urology, 2021, 205, 1055-1062.	0.4	12
15	Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Diagnostics, 2021, 11, 663.	2.6	16
16	ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer. Journal of the American College of Radiology, 2021, 18, S212-S228.	1.8	4
17	Ovarian-Adnexal Reporting Lexicon for MRI: A White Paper of the ACR Ovarian-Adnexal Reporting and Data Systems MRI Committee. Journal of the American College of Radiology, 2021, 18, 713-729.	1.8	50
18	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology, 2021, 299, 494-507.	7.3	26

#	ARTICLE	IF	CITATIONS
19	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e17-495.e24.	1.6	1
20	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: <i>Radiology</i> Scientific Expert Panel. Radiology, 2021, 300, E323-E327.	7.3	117
21	Emergency room imaging in pediatric patients with cancer: analysis of the spectrum and frequency of imaging modalities and findings in a tertiary cancer center and their relationship with survival. Cancer Imaging, 2021, 21, 51.	2.8	0
22	<i>BJR</i> female genitourinary oncology special feature: introductory editorial. British Journal of Radiology, 2021, 94, 20219003.	2.2	0
23	Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2020, 214, 597-604.	2.2	21
24	Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers, 2020, 12, 2994.	3.7	49
25	ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer. Journal of the American College of Radiology, 2020, 17, S472-S486.	1.8	20
26	Accelerating Prostate Diffusion-weighted MRI Using a Guided Denoising Convolutional Neural Network: Retrospective Feasibility Study. Radiology: Artificial Intelligence, 2020, 2, e200007.	5.8	23
27	Unraveling tumorâ€“immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
28	Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis. European Radiology, 2020, 30, 5560-5577.	4.5	42
29	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 306-315.	5.4	97
30	Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes. Emergency Radiology, 2020, 27, 413-421.	1.8	1
31	The urachus revisited: multimodal imaging of benign & malignant urachal pathology. British Journal of Radiology, 2020, 93, 20190118.	2.2	8
32	Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. European Radiology, 2020, 30, 4306-4316.	4.5	25
33	Doctor, a patient is on the phone asking about the endorectal coil!. Abdominal Radiology, 2020, 45, 4003-4011.	2.1	2
34	Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. Abdominal Radiology, 2020, 45, 3882-3895.	2.1	11
35	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.4	58
36	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28

#	ARTICLE	IF	CITATIONS
37	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 16.	1.5	17
38	The Diagnostic Performance of the Length of Tumor Capsular Contact on MRI for Detecting Prostate Cancer Extraprostatic Extension: A Systematic Review and Meta-Analysis. <i>Korean Journal of Radiology</i> , 2020, 21, 684.	3.4	23
39	Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 432-434.	0.5	5
40	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 1121-1121.	0.4	0
41	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019, 292, 273-286.	7.3	46
42	ACR Appropriateness Criteria® Gestational Trophoblastic Disease. <i>Journal of the American College of Radiology</i> , 2019, 16, S348-S363.	1.8	7
43	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>European Urology Oncology</i> , 2019, 2, 605-616.	5.4	30
44	The Diagnostic Performance of MRI for Detection of Extramural Venous Invasion in Colorectal Cancer: A Systematic Review and Meta-Analysis of the Literature. <i>American Journal of Roentgenology</i> , 2019, 213, 575-585.	2.2	35
45	Contemporary Management of Hemorrhage After Minimally Invasive Radical Prostatectomy. <i>Urology</i> , 2019, 130, 120-125.	1.0	8
46	Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. <i>Abdominal Radiology</i> , 2019, 44, 2864-2873.	2.1	8
47	Contribution of Radiology to Staging of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 294-301.	4.6	17
48	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	7.1	426
49	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	5.0	23
50	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1516-1523.	5.0	20
51	Advances in imaging. <i>Nature Reviews Urology</i> , 2018, 15, 81-82.	3.8	0
52	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	1.6	110
53	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
54	ACR Appropriateness Criteria® Postmenopausal Subacute or Chronic Pelvic Pain. <i>Journal of the American College of Radiology</i> , 2018, 15, S365-S372.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. <i>Urology</i> , 2018, 119, 55-61.	1.0	2
56	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	1.9	372
57	Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. <i>American Journal of Roentgenology</i> , 2017, 208, 849-853.	2.2	31
58	The performance of PI-RADSV2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. <i>Abdominal Radiology</i> , 2017, 42, 1968-1974.	2.1	13
59	Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. <i>Abdominal Radiology</i> , 2017, 42, 2488-2512.	2.1	30
60	High-Grade Serous Ovarian Cancer: Associations between <i>BRCA</i> Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. <i>Radiology</i> , 2017, 285, 472-481.	7.3	46
61	Author Reply. <i>Urology</i> , 2017, 102, 172.	1.0	0
62	Detection of Clinically Significant Prostate Cancer: Short Dualâ€”Pulse Sequence versus Standard Multiparametric MR Imagingâ€”A Multireader Study. <i>Radiology</i> , 2017, 284, 725-736.	7.3	62
63	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	4.5	92
64	Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. <i>European Radiology</i> , 2017, 27, 2903-2915.	4.5	128
65	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	28.9	368
66	From Staging to Prognostication. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2017, 25, 611-633.	1.1	40
67	Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. <i>Radiology</i> , 2017, 285, 482-492.	7.3	52
68	Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. <i>Abdominal Radiology</i> , 2017, 42, 271-277.	2.1	17
69	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	1.0	52
70	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
71	Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. <i>Journal of Urology</i> , 2016, 196, 697-702.	0.4	47
72	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e9-530.e14.	1.6	10

#	ARTICLE	IF	CITATIONS
73	Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng/ml following prostatectomy: How much information can conventional imaging provide?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 482.e5-482.e10.	1.6	28
74	The expanding landscape of diffusion-weighted MRI in prostate cancer. Abdominal Radiology, 2016, 41, 854-861.	2.1	8
75	Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses. Radiology, 2016, 280, 446-454.	7.3	136
76	Molecular Imaging of Prostate Cancer. Radiographics, 2016, 36, 142-159.	3.3	83
77	Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. European Radiology, 2016, 26, 1606-1612.	4.5	279
78	Second-Opinion Interpretations of Gynecologic Oncologic MRI Examinations by Sub-Specialized Radiologists Influence Patient Care. European Radiology, 2016, 26, 2089-2098.	4.5	47
79	Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 1-10.	1.1	12
80	Association between Morphologic CT Imaging Traits and Prognostically Relevant Gene Signatures in Women with High-Grade Serous Ovarian Cancer: A Hypothesis-generating Study. Radiology, 2015, 274, 742-751.	7.3	50
81	Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. European Radiology, 2015, 25, 2840-2850.	4.5	322
82	Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. European Radiology, 2015, 25, 1294-1302.	4.5	16
83	Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Subspecialized Genitourinary Oncologic Radiologists. American Journal of Roentgenology, 2015, 205, W73-W78.	2.2	74
84	Ovarian Cancer from Anatomy to Functional Imaging. Current Radiology Reports, 2015, 3, 1.	1.4	1
85	Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. European Radiology, 2015, 25, 3348-3353.	4.5	43
86	Role of MRI in the diagnosis and management of prostate cancer. Future Oncology, 2015, 11, 2757-2766.	2.4	10
87	Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology, 2015, 138, 554-559.	1.4	16
88	Imaging Features of Uncommon Gynecologic Cancers. American Journal of Roentgenology, 2015, 205, 1346-1359.	2.2	17
89	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. Clinical Imaging, 2015, 39, 94-98.	1.5	17
90	Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World Journal of Radiology, 2015, 7, 184.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Response. Radiology, 2015, 274, 625.	7.3	3
92	Anatomic segmentation improves prostate cancer detection with artificial neural networks analysis of ¹ H magnetic resonance spectroscopic imaging. Journal of Magnetic Resonance Imaging, 2014, 40, 1414-1421.	3.4	24
93	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology, 2014, 271, 220-229.	7.3	88
94	Value of a Standardized Lexicon for Reporting Levels of Diagnostic Certainty in Prostate MRI. American Journal of Roentgenology, 2014, 203, W651-W657.	2.2	39
95	Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score. Clinical Cancer Research, 2014, 20, 3705-3711.	7.0	69
96	PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nuclear Medicine and Biology, 2014, 41, 410-418.	0.6	33
97	Association Between Penile Dynamic Contrast-Enhanced MRI-Derived Quantitative Parameters and Self-Reported Sexual Function in Patients with Newly Diagnosed Prostate Cancer. Journal of Sexual Medicine, 2014, 11, 2581-2588.	0.6	5
98	Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3+4 prostate cancer. European Radiology, 2014, 24, 3161-3170.	4.5	34
99	Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. European Journal of Radiology, 2014, 83, 1169-1176.	2.6	109
100	The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 701-707.	6.4	2
101	MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. European Journal of Radiology, 2013, 82, e775-e781.	2.6	19
102	The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecologic Oncology, 2013, 129, 586-592.	1.4	40
103	Magnetic Resonance Imaging-Targeted Prostate Biopsies: Now Is the Time to START. European Urology, 2013, 64, 553-554.	1.9	2
104	MRI of ovarian masses. Journal of Magnetic Resonance Imaging, 2013, 37, 265-281.	3.4	43
105	Multiparametric Prostate MR Imaging with T2-weighted, Diffusion-weighted, and Dynamic Contrast-enhanced Sequences: Are All Pulse Sequences Necessary to Detect Locally Recurrent Prostate Cancer after Radiation Therapy?. Radiology, 2013, 268, 440-450.	7.3	109
106	Multiphase contrast-enhanced MRI: Single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. Journal of Magnetic Resonance Imaging, 2013, 37, 1160-1167.	3.4	35
107	Magnetic Resonance Imaging/Positron Emission Tomography Provides a Roadmap for Surgical Planning and Serves as a Predictive Biomarker in Patients With Recurrent Gynecological Cancers Undergoing Pelvic Exenteration. International Journal of Gynecological Cancer, 2013, 23, 1512-1519.	2.5	28
108	MR Imaging of Treated Prostate Cancer. Radiology, 2012, 262, 26-42.	7.3	120

#	ARTICLE	IF	CITATIONS
109	Value of the Hemorrhage Exclusion Sign on T1-weighted Prostate MR Images for the Detection of Prostate Cancer. Radiology, 2012, 263, 751-757.	7.3	80
110	Normal Central Zone of the Prostate and Central Zone Involvement by Prostate Cancer: Clinical and MR Imaging Implications. Radiology, 2012, 262, 894-902.	7.3	104
111	Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. Radiology, 2012, 265, 478-487.	7.3	81
112	The Incremental Value of Contrast-Enhanced MRI in the Detection of Biopsy-Proven Local Recurrence of Prostate Cancer After Radical Prostatectomy: Effect of Reader Experience. American Journal of Roentgenology, 2012, 199, 360-366.	2.2	51
113	Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. European Journal of Radiology, 2012, 81, 4131-4137.	2.6	66
114	Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer. Journal of Urology, 2012, 188, 1732-1738.	0.4	201
115	Renal Cortical Tumors: Use of Multiphasic Contrast-enhanced MR Imaging to Differentiate Benign and Malignant Histologic Subtypes. Radiology, 2012, 264, 779-788.	7.3	86
116	Reducing the influence of b ⁰ -value selection on diffusion-weighted imaging of the prostate: Evaluation of a revised monoexponential model within a clinical setting. Journal of Magnetic Resonance Imaging, 2012, 35, 660-668.	3.4	32
117	The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. Imaging in Medicine, 2011, 3, 333-343.	0.0	2
118	Primary seminal vesicle adenocarcinoma. Clinical Imaging, 2011, 35, 480-482.	1.5	13
119	Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. European Radiology, 2011, 21, 1970-1978.	4.5	79
120	Pleural Effusion Detected at CT prior to Primary Cytoreduction for Stage III or IV Ovarian Carcinoma: Effect on Survival. Radiology, 2011, 258, 776-784.	7.3	44
121	The Value of MR Imaging When the Site of Uterine Cancer Origin Is Uncertain. Radiology, 2011, 258, 785-792.	7.3	39
122	Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness. Radiology, 2011, 259, 775-784.	7.3	377
123	Pelvic Imaging Following Chemotherapy and Radiation Therapy for Gynecologic Malignancies. Radiographics, 2010, 30, 1843-1856.	3.3	74
124	Residual Prostate Tissue After Radical Prostatectomy: Acceptable Surgical Complication or Treatment Failure?. Urology, 2010, 76, 1136-1137.	1.0	3
125	Left Gastric Artery Aneurysm: Successful Embolization with Ethylene Vinyl Alcohol Copolymer (Onyx). CardioVascular and Interventional Radiology, 2008, 31, 418-421.	2.0	13
126	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. JNCI Cancer Spectrum, 0, , .	2.9	2